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Abstract
Background: Depression and anxiety remain under-diagnosed and under-treated in those with neurologic diseases
such as dementia or Parkinson’s Disease (PD). Our objectives were to first, to provide a synthesis of high quality
guidelines available for the identification and management of depression or anxiety in those with dementia or PD.
Second, to identify areas for improvement for future guidelines.
Methods: We searched MEDLINE, PsycINFO, and EMBASE (2009 to July 24, 2015), grey literature (83 sources; July 24-
Sept 6, 2015), and bibliographies of included studies. Included studies were evaluated for quality by four
independent reviewers the AGREE II tool. Guideline characteristics, statements and recommendations relevant to
depression or anxiety for dementia and PD were then extracted. (PROSPERO CRD: 42016014584)
Results: 8121 citations were reviewed with 31 full text articles included for assessment with the AGREE II tool. 17
were of sufficient quality for inclusion. Mean overall quality scores were between 4.25 to 6.5. Domain scores were
lowest in the areas of stakeholder involvement, applicability, and editorial independence.
Recommendations for the screening and diagnosis of depression were found for PD and dementia. There was little
evidence to guide diagnosis or management of anxiety. Non-pharmacologic therapies were recommended for
dementia patients. Most advocated pharmacologic treatment for depression, for both PD and dementia, but did
not specify an agent due to lack of evidence.
Conclusions: The available recent high quality guidelines outline several recommendations for the management of
comorbid depression or anxiety in PD or dementia. However there remain significant gaps in the evidence.
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Background
Persons experiencing neurologic disorders, such as de-
mentia or Parkinson’s disease (PD), and depressive or
anxiety disorders have poorer outcomes with reduced
quality of life, poor functional status and worsened cog-
nition [1–8].
It is estimated that the prevalence of depression in de-
mentia is approximately 25% with anxiety occurring in
up to 75% [7, 9–11]. In PD, approximately 17% of
patients experience major depression and anxiety be-
tween 3.6 to 40% [2, 12].
Despite awareness of these comorbidities, depression
and anxiety remain under-diagnosed and under-treated
in those with neurologic diseases [1, 3, 13–17]. Only
20% of PD patients diagnosed with depression receive
therapy [18]. This represents a significant knowledge-to-
practice gap. One way to address this is through the use
of Clinical Practice Guidelines (CPGs) [19]. CPGs
synthesize available evidence based on a systematic re-
view of the literature, clinical expertise and patient pref-
erences [19]. CPGs are targeted at practitioners who
apply the recommendations to clinical decision-making
and reduce disparities in care [19–22].
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Thus, in the setting of PD and dementia, CPGs should
enable the appropriate management of depression and
anxiety [23–26]. Despite available CPGs, these disorders
remain under-managed, suggesting these CPGs are un-
derused or lack sufficient recommendations [26–28].
Multiple available guidelines of varied quality leads to
uncertainty as to which CPGs should be used in prac-
tice. Our primary aim is to synthesize the high-quality
evidence-based CPGs available for diagnosis, and man-
agement of depression or anxiety in those with dementia
or PD. We chose to summarize and evaluate guidelines
as the majority of physicians will use CPGs as a tool to
review evidence and inform practice. Secondarily we aim
to, identify areas gaps within the existing guidelines to
inform future guideline development. This provides a
broad over view of evidence in the area and identifies
areas for further study and development.
Methods
The study protocol follows the recommendations pro-
vided by the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA)—Protocols State-
ment [29] and guidelines and the protocol was registered
with PROSPERO [30] (CRD: 42016014584).
Search strategy
The literature search was developed in conjunction with
an experienced librarian (DL) and was verified independ-
ently by a second librarian (HLR), using the Peer Review
of Electronic Search Strategies (PRESS) methodology
[31]. Any recommendations were incorporated into the
final search.
Databases included MEDLINE, EMBASE, and Psy-
cINFO. Clusters of terms (controlled vocabulary and key
words) were used to search each database; these include
dementia, Parkinson’s disease, depression, anxiety and
CPGs (Additional file 1: Box S1). The search was com-
pleted by cluster, first searching the terms in each cluster
(combined with the Boolean operator ‘OR’) and keyword
searches of abstracts and titles. The clusters were then
combined with ‘AND’. We searched for several patho-
logical variants of dementia including Alzheimer’s disease,
vascular, frontotemporal, Lewy Body disease, Huntington’s
Disease, CADASIL, primary progressive aphasia, and
Creutzfeldt Jakob (Additional file 1: Box S1). We included
relevant derivatives of terms or broad key words related to
depressive or anxiety disorders (Additional file 1: Box S1).
This was augmented by a search of the grey literature
(Additional file 2: Table S1). This search was limited
from 2009 to search date, such that we would only cap-
ture CPGs developed within the past 5 years; given the
evidence that CPGs may become out of date after only
3 years [32]. All languages were included in this search.
Selection & eligibility
All citations were reviewed for eligibility by two inde-
pendent authors; citations meeting initial eligibility cri-
teria were included in full text review. If there was
disagreement at the abstract stage, the full article was
pulled for review. Bibliographies for all included articles
were searched. If multiple CPGs were identified from a
single agency on the same topic the most recent was
used.
At the first stage of abstract review, any article that
represented a guideline for PD or dementia was in-
cluded. Eligibility at the full text stage required that the
CPGs included at least one recommendation related to
depression and/or anxiety in patients with PD and/or
dementia. The kappa statistic was used to quantify inter-
rater reliability.
For non-English articles that met eligibility at the full
text stage, the language was determined using online
translation software. Citations were translated using the
online (Google translate) function to determine if an art-
icle was a guideline. When included, the documents
were searched using translated relevant terms; for ex-
ample, if a guideline pertained to PD in the abstract, the
text was searched for depression or anxiety (and all
translated synonyms). If those criteria were met, the full
guideline was translated and reviewed.
Assessment of quality
The Appraisal of Guidelines Research & Evaluation
(AGREE II) tool was used to assess guideline quality
[33]. This tool was designed to evaluate guideline quality
and to aid in guideline development and reporting [33].
The tool includes 6 domains covering scope and pur-
pose, stakeholder involvement, rigour of development,
clarity of presentation, applicability and editorial inde-
pendence [33]. Within each domain there are between 2
to 8 questions, to a total of 23 [33]. Each item is rated
from 1 (not included or very poorly reported) to 7 (ex-
ceptional reporting of all criteria outlined in the AGREE
II Manual) [33].
Each domain was scored independently by four re-
viewers, along with the assignment of an overall score.
An initial assessment of 5 citations was done and com-
pared across all 4 reviewers [33]. The 4 reviewers met to
discuss discrepancies and address questions about rating,
before the remainder of the guidelines were reviewed
and scored. This also served to ensure that all raters
were aligned in their understanding of the AGREE II
items. Any further discrepancies were resolved by
discussion.
Domain scores pooled across the 4 assessors were cal-
culated, as outlined in the AGREE II user manual [33].
The higher score indicates a higher quality across rated
items. It has been demonstrated that the quality across
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the AGREE II domains predicts guideline implementa-
tion [33]. The mean overall quality scores with standard
deviations (SD) were calculated, as well as for each do-
main item. CPGs with a mean overall quality score 5 or
greater were assigned at least moderate quality and in-
cluded in further analysis. CPGs with a score below 3
were excluded due to low quality. A score less than 5
but greater than 3 were re-evaluated and inclusion status
was decided by consensus.
Data extraction & synthesis of evidence
Guideline characteristics were extracted by one author
(ZG) and independently verified by a second author
(BM). Items extracted included the primary conditions
covered, region/organizations, number of committee
members, numbers of references, and sources of
funding.
Two independent reviewers then extracted relevant rec-
ommendations (ZG, BM). Specifically, guidelines were
searched for any mention of relevant recommendations
and supporting text or statements. Three authors
reviewed the extracted recommendations (ZG, BM and
JHL). Recommendations were compiled across the guide-
lines into relevant categories and subcategories, and re-
ported using descriptive statistics including the quality,
number of guidelines supporting the statement and sub-
populations included. As the evidence in the guidelines is
represented by practice recommendations, it was not
amenable to meta-analysis. The main output of this sys-
tematic review was an appraisal of the quality of all guide-
lines pertaining to comorbid depression or anxiety in PD
or dementia, and a synthesis of the recommendations
across the different guidelines. Data were analyzed using
STATA 13.1 (Stata Corp. College Station, TX).
Results
Study selection
The database search generated 4441 citations after du-
plicates were removed, with a further 3681 citations
identified from the grey literature (Fig. 1). When
screened for eligibility, 360 citations met criteria for full
text review (κ = 0.88, 95.7% agreement). At this stage
most articles were excluded because they were not rele-
vant (n = 218), were not guidelines, or were unrelated
guidelines. Other common reasons for exclusion at the
full text stage were being out of the date range (n = 33)
or a duplicate (n = 35). Excluded citations also included
26 mental health guidelines that did not address PD or
dementia. Similarly there were 5 PD and 9 dementia
guidelines that did not address depression or anxiety.
The dementia guidelines primarily pertained to Alzhei-
mer’s disease, vascular dementia, general dementia care
and one referred to Lewy Body Disease. Of these articles,
4 were identified to be summary documents of included
guidelines and were used as supplemental material to
these included guidelines. Twenty-six CPGs met all eligi-
bility criteria and were evaluated using the AGREE II
tool, of which 17 met the quality cut off for inclusion.
Guideline characteristics
The 17 included guidelines addressed PD (n = 5), demen-
tia (n = 8) and mental health (n = 4) CPGs (Table 1). They
included recommendations from many regions, including
Canada (n = 2), USA (n = 3), Pan-European (n = 4), UK
(n = 2), Scotland (n = 1), Spain (n = 2), South Korea (n = 1)
and international (n = 2). The associations or organiza-
tions are outlined in Table 1. All guidelines used a method
for grading the evidence (Additional file 3: Figure S1).
Most guidelines were funded through government or
non-commercial funding; only two CPGs had some
pharmaceutical funding.
Study quality
These 26 CPGs were assessed for quality using all 23
items across the 6 domains of the AGREE II tool. Nine
guidelines were excluded for low quality. Six were ex-
cluded with an overall mean rating ranging from 2.25 to
3.75. Three had ratings of 4–4.5, where decision to ex-
clude was by consensus. A low rating was typically due
to unclear methods; thus scoring low on rigour of devel-
opment, applicability and editorial independence. Au-
thors of guidelines were contacted for more information
in the case that an item was unclear and responses were
incorporated in the quality assessment.
The 17 included guidelines had mean overall scores
from 4 to 6.5 (Table 2). When examining the individual
domain scores, the highest rated domain was Domain 4:
Clarity of Presentation (mean score 77.0; SD 11.4). This
was followed by Domain 1: Scope and Purpose (mean
score 72.1; SD 12.1). Domain 5: Applicability was the
lowest rated domain (mean score 41.5; SD 22.6). Stake-
holder involvement (Domain 2) also had a low score
(mean score 54.5; SD 23.3).
The mean rating across each question in the domain
scores were also examined to explore differences be-
tween domains (Additional file 4: Table S2). Question
one pertaining to the overall objectives was the highest
rated item at 5.88 (SD 0.61), followed by link between
evidence and recommendations at 5.78 (SD 0.51). The
lowest rated item was providing a procedure for updat-
ing the guideline is provided, with a mean rating of 3.16
(SD 1.73). The views and preferences of the target popu-
lation have been sought was also rated poorly with a
mean score of 3.25 (SD 1.92). All items in Domain 5 had
low mean scores, ranging between 3.27 (SD 1.46) for re-
source implications and 3.72 (SD 1.53) for advice on
putting recommendations into practice.
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Guideline recommendations
The details of extracted recommendations are summa-
rized in the Table 3 for PD and Table 4 for dementia. 21
categories of recommendations were extracted in total.
Parkinson’s disease recommendations
Only two guidelines discussed anxiety in those with PD
[34, 35]. These stated there was little evidence for either
the diagnosis or treatment of anxiety in PD, and that
there was insufficient evidence for the treatment of anx-
iety with levodopa [34, 35].
There were clear recommendations surrounding the
diagnosis of depression in PD [34, 37, 38]. Clinicians
should have a low threshold for the diagnosis of depres-
sion in PD given the difficulties making a diagnosis [34].
Use of a validated tool for detecting depression (or neuro-
psychiatric symptoms) was advocated by two guidelines,
with varying levels of recommendations [37, 38]. Tools
that were recommended include the HDRS, the MADRS
or the UPDRS—Part 1 Non-Motor, among others [37, 38].
The diagnosis should be made based on a clinical inter-
view and not based on the tool alone and should seek col-
lateral information from carers [37].
Antidepressant therapy is recommended, however
there is little evidence to support one agent over another
(n = 2) [37, 39]. Additionally, the choice of an agent must
be individualized (n = 1) and the practitioner should con-
sider side effects and drug interactions prior to initiation
[34]. There have been prior studies on the tricyclic anti-
depressants (TCAs), specifically amitriptyline, and al-
though they were beneficial for mood, this was offset by
the side effects (n = 3) [34, 37, 39]. One guideline noted
that selective serotonin reuptake inhibitors (SSRIs)
showed some benefit in uncontrolled studies [39, 40],
but noted that the SSRIs could worsen PD symptoms of
restless legs (RLS), periodic limb movement (PLM) and
Fig. 1 PRISMA Flow Diagram
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Table 1 Guideline Characteristics














The American Academy of Neurology
(AAN)





PD Diagnosis Treatment Scotland 20 189 Y Y G 6
Grimes et al.
(2012)c [34]
Canadian Neurological Sciences Federation
(CNSF) & Parkinson Society Canada
PD Diagnosis Treatment Canada 22 62 Y Y NC & P 6.5
Berardelli et al.
(2013) [38]
European Federation of Neurological
Societies & Movement Disorder Society—
European Section (EFNS-MDS-ES)
PD Diagnosis Europe 25 245 Y Y NS h 5
Ferreira et al.
(2013) [40]
European Federation of Neurological
Societies & Movement Disorder Society—
European Section (EFNS-MDS-ES)
PD Treatment Europe 22 363 Y Y NC 4.5
Hort et al.
(2010) [47]
European Federation of Neurological
Societies (EFNS)
Dementia Diagnosis Treatment Europe 8 100 Y Y NC 4.25
No Author
(2010) [42]
Ministry of Health, Social Services and
Equality & Agency for Health Quality
and Assessment of Catalonia (AIAQS)
Dementia Diagnosis Treatment Spain 67 688 Y Y NC & G 5.75
No Author
(2011)d [41]
National Institute for Health and Care
Excellence, National Collaborating
Centre for Mental Health, British
Psychological Society & The Royal
College of Psychiatrists (NICE)
Dementia Diagnosis & Treatment UK 28 NNh Y Y NC & G 6.5
Ihl et al.
(2011) [44]
World Federation of Societies of
Biological Psychiatry (WFSBP)
Dementia Treatment International 39 215f Y Y NC 4.5
No Author
(2011) [43]
Clinical Research Centre for
Dementia (CRCD)





Dementia Treatment UK 16 148f N Y NC & P 4
Sorbi et al.
(2012) [45]
European Federation of Neurological
Societies & European Neurological
Society (EFNS-ES)




on the Diagnosis and Treatment
of Dementia (CCCDTD4)





Depression Treatment USA 7 1170 Y Y NC 4.75

















Ministry of Health, Social Services and
Equality & Galician Health Technology
Assessment Agency (Availia-T)
Suicide Diagnosis Treatment Spain 24 683 Y Y NC & G 5
Mitchell et al.
(2013) [48]
Institute for Clinical Systems
Improvement (ICSI)
Depression Diagnosis Treatment USA 14 331 Y Y NC 5.75
a Dementia guidelines primarily included Alzheimer’s disease, vascular dementia, general dementia care and one referred to Lewy Body Disease
b Includes Grosset et al. [54]
c Includes Patel et al. [61]
d Originally created in 2007 and updated in 2011
e Includes Moore et al. [62], Herrman et al. [63]
f Number counted from the text
g Includes Recommendations Referenced in Rabin et al. [64]
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REM sleep behaviour disorder (RBD) (n = 2) [39, 40]. It
is recommended to avoid amoxapine and lithium in
those with PD, due to the risk of worsening motor
symptoms (n = 1) [39].
There is some weak evidence supporting the use of
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drugs addressing the motor symptoms [34]. However
there was no evidence levodopa alone affected mood [40].
Other therapies for depression are not well explored in
PD. The European Federation of Neurological Sciences
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(EFNS) concluded there was insufficient data to recom-
mend psychotherapy, electroconvulsive therapy (ECT)
or transcranial magnetic stimulation (TCMS) [40]. Other
guideline assert that ECT has been used in PD, but that
there are no specific trials in PD and is associated with
risk (n = 2) [34, 39].
Dementia recommendations
It is recommended that patients with dementia be
assessed for anxiety (n = 2), however there is no clear con-
sensus on what tools to use [41, 42]. One guideline recom-
mended the use of the Hospital Anxiety Depression Scale
[42]. The evidence for the treatment of anxiety in demen-
tia is lacking (n = 1) [42].
It is recommended that patients with dementia be eval-
uated and re-evaluated over time for depression (n = 5)
[41–45]. As part of this assessment, patients should be
evaluated for other secondary causes of depression. It is
suggested that these patients be assessed for suicidality by
one guideline [39], however another reported there was
inconclusive evidence regarding this [46].
The use of a valid screening tool was recommended
for depression case finding (n = 5) in dementia, including
the CSDD, GDS or Dementia Mood Assessment Scale
(DMAS) [39, 42, 45, 47, 48]. The CSDD was more com-
monly recommended given it is a clinician-rating tool
that involves caregivers with higher sensitivity (n = 4)
[39, 45, 47, 48].
Therapy for depression in those with dementia should in-
clude a variety of non-pharmacologic options (n = 4) such
as stimulation oriented, cognitive behavioural, reminis-
cence, exercise or multi-sensory therapy [39, 41, 42, 48].
Pharmacologic therapy is recommended despite variable
evidence (n = 6) [41, 42, 44, 45, 49, 50]. It is suggested by
one guideline that, if there is no improvement with non-
pharmacologic therapy, an antidepressant be considered
[50]. Another notes that for moderate-severe depression,
pharmacologic treatment is warranted (n = 1) [49]. How-
ever, there needs to be a clear risk-benefit assessment and
discussion (n = 1) [41]. Based largely on clinical experience,
most guidelines recommend the use of SSRIs given the
lower side effect profile over TCAs (n = 6) [39, 41, 42, 45,
49, 50]. The concern with TCAs is largely anticholinergic
side effects causing worsened cognition [42, 50]. Other
Table 3 Statements & recommendations for Parkinson’s disease
Anxiety
Evidence for the Management & Treatment of Anxiety in PD is Lacking.
Level of Evidence
AAN Level U
(Uncertain or Lack of Evidence)
Guidelines Zesiewicz et al. (2010) [35], Grimes et al. (2012) [34]
Depression
Screening for Depression in PD is recommended.
Level of Evidence
EFNS Level A (Effective), SIGN Grade C
(Case Control to Cohort Evidence)
Guidelines Berardelli et al. (2013) [38], Grosset et al. (2010) [54]
There are several available tools screening for Depression in PD.
Level of Evidence
SIGN Level C & Good Practice Point
(GDS, BDI, HADS, MADRS & HDRS) & EFNS
Class I (Diagnostic Accuracy Study)(MDS-UPDRS)
Guidelines Grosset et al. (2010) [54], Berardelli et al. (2013) [38]
Comment A patient with PD should be screened for
depression with either a clinician or self-rated
tool. Diagnosis should not be based on the solely
on the tool. Those with a positive screening test
should be referred for further assessment and
diagnosis (including collateral history).
Practitioners should have a low threshold for diagnosing Depression in PD.
Level of Evidence
CFNS Good Practice Point
Guidelines Grimes et al. (2012) [34]
Treatment of Depression in PD needs to be individualized to each case.
Level of Evidence
CFNS Good Practice Point
Guidelines Grimes et al. (2012) [34]
Anti-depressant Therapy is recommended; there is little evidence to
suggest one agent over another.
Guidelines Gelenberg et al. (2010) [39], Grosset et al. (2010) [54]
Tricyclic Antidepressants (e.g. Amitriptyline or Desipramine) have some
evidence for treatment, but this must be balanced with the adverse
effects (e.g. Anticholinergic).
Level of Evidence
CFNS Level C (Possibly Effective)
Guidelines Grimes et al. (2012) [34], Grosset et al. (2010) [54],
Gelenberg et al. (2010) [39]
Selective Serotonin Reuptake Inhibitors have some evidence for
treatment, but this must be balanced with the adverse effects
(e.g. RLS, PLM, RBD).
Level of Evidence
EFNS Class II (Prospective Matched Group Cohort
or Controlled Trial) to Class IV (Uncontrolled Studies),
APA Level II (Moderate Clinical Evidence)
Guidelines Ferreira et al. (2013) [40], Gelenberg et al. (2010) [39]
Certain agents such as Amoxapine or Lithium should be avoided due to
worsening of PD Symptoms.
Guidelines Gelenberg et al. (2010) [39]
There is some evidence for the use of dopamine agonists (e.g. Pramipexole)
& MAOI (e.g. Selegiline) for depression, but not for levodopa.
Level of Evidence
EFNS Class I (RCT),
Class III (Other Controlled Trial), APA Level I
(Recommended with substantial confidence)
Table 3 Statements & recommendations for Parkinson’s disease
(Continued)
Guidelines Ferreira et al. (2013) [40], Gelenberg et al. (2010) [39],
Grimes et al. (2012) [34]
There is insufficient evidence regarding the use of ECT, TCMS and
psychotherapy in depression with PD.
Guidelines Ferreira et al. (2013) [40], Gelenberg et al. (2010) [39],
Grimes et al. (2012) [34]
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antidepressants such as mirtazapine, bupropion, and venla-
faxine may also be of benefit (n = 1) [42]. Other adjunct
therapies recommended include stimulants (n = 2) [39, 42],
cholinesterase inhibitors (n = 1) [42] and ECT on a
case-by-case basis (n = 1) [39].
Discussion
This study provides a synthesis and quality assessment
of available guidelines for the management of depression
or anxiety in PD or dementia. We identified clear gaps
in guideline quality and the evidence, which inform fu-
ture research and knowledge translation.
Table 4 Statements & recommendations for Dementia
Anxiety
Patients with Dementia should be assessed for Anxiety (e.g. HADS).
Level of Evidence
AIAQS Level D (Expert Opinion)
Guidelines AIAQS (2010) [42], NICE (2011) [41]
Psychological Interventions can be considered for Anxiety in Dementia
Guidelines NICE (2011) [41]
There is little evidence about the treatment of Anxiety in those with
Dementia.
Cholinesterase Inhibitors can be considered for treating Dementia-
related behaviours, including anxiety.
Level of Evidence
AIAQS Level A (Meta-analysis or RCT)
Guidelines AIAQS (2010) [42]
Depression
Patients experiencing Dementia should be evaluated for Depression,
including possible secondary causes.
Level of Evidence
CRCD Level A (Useful), AIAQS Level D, WFSBP Grade 3
(Limited Evidence from Controlled Studies), EFNS GPP
Guidelines NICE (2011) [41], AIAQS (2010) [42], CRCD (2011) [43],
Sorbi et al (2012) [45], Ihl et al. (2011) [44]
Patients with Depression in Dementia should be evaluated for suicide
risk, however evidence varies.
Level of Evidence
APA Level I (Substantial Clinical Confidence) or
Inconclusive
Guidelines Gelenberg et al. (2010) [39], Avalia-T (2012) [46]
Use of a valid screening tool (e.g. CSDD, GDS, HADS or DMAS) for
Depression is recommended.
Level of Evidence
AIAQS Level D to Good Practice Point, Low Quality
Evidence, EFNS GPP/Class II (Prospective Study)
Guidelines Gelenberg et al. (2010) [39], AIAQS (2010) [42],
Sorbi et al (2012) [45], Hort et al (2010) [47],
Mitchell et al. (2013) [48]
fMRI needs further study to determine its utility in Depression in the
context of Dementia
Level of Evidence
CCCDT4 Grade 2C (Moderate Recommendation,
Low Level Evidence)
Guidelines Gauthier et al. (2012) [50]
Therapy for Depression in Dementia should include a variety of Non-
pharmacologic options.
Level of Evidence
AIAQS Level C (Case-control, Cohort), APA Level II
(Moderate Clinical Confidence)
Guidelines NICE (2011) [41], AIAQS (2010) [42], Gelenberg et al.
(2010) [39], Mitchell et al. (2013) [48]
Comment These include: cognitive behavioural therapy,
reminiscence therapy, multi-sensory stimulation,
animal-assisted therapy, exercise, stimulation-oriented
treatment (recreational or pleasurable activities), or
improvements to a living situation. Consider
the involvement of carers.
Although evidence is mixed, a trial of Anti-depressants could be considered
for Depression in Dementia.
Level of Evidence
CCCDT4 Grade 2A (Moderate Recommendation,
High Level Evidence), EFNS Class IV (Un-blinded,
Table 4 Statements & recommendations for Dementia
(Continued)
Expert Opinion), WFSBP Grade 5 (Inconsistent Results),
APA Level II (Moderate Clinical Confidence)
Guidelines Gauthier et al. (2012) [50], NICE (2011) [41], Sorbi et al
(2012) [45], Gelenberg et al. (2010) [39], Ihl et al. (2011)
[44], Dua et al (2011) [49]
When choosing an anti-depressant (E.g. SSRIs, SNRIs or TCAs) it is
important to consider the anticholinergic side effects.
Level of Evidence
EFNS Level B (Case-control, Cohort), EFNS Class IV
(Un-blinded, Expert Opinion), APA Level I
(Substantial Clinical Confidence) to APA Level II
(Moderate Clinical Confidence), AIAQS Level B
Guidelines Gauthier et al. (2012) [50], NICE (2011) [41],
Sorbi et al (2012) [45], Hort et al (2010) [47],
Gelenberg et al. (2010) [39], AIAQS (2010) [42]
Comment SSRIs (Citalopram or Sertraline) and TCAs have similar
efficacy, but TCAs are not recommended given
anticholinergic effects. SSRIs appear to be better
tolerated. Other agents such as bupropion,
venlafaxine and mirtazapine may be effective.
Stimulants can be considered for treatment of Depression in Dementia.
Level of Evidence
APA Level III (Depends on Individual Circumstances),
AIAQS Level B (Case-control, Cohort)
Guidelines Gelenberg et al. (2010) [39], AIAQS (2010) [42]
Cholinesterase Inhibitors can be considered for treating Dementia-
related behaviours, including depression.
Level of Evidence
AIAQS Level A (Meta-analysis or RCT)
Guidelines AIAQS (2010) [42]
ECT can be considered in certain cases for Depression in those with
Dementia.
Level of Evidence
APA Level II (Moderate Clinical Confidence)
Guidelines Gelenberg et al. (2010) [39]
Cholinesterase Inhibitors may improve neuropsychiatric symptoms in
Lewy Body Disease
Level of Evidence
Level A (Meta-analysis or RCT)
Guidelines O’Brien et al (2011) [60]
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Guideline quality
Guidelines that were excluded due to low quality were
typically those that lacked explicit development
methods, thus ratings across all the domains were low.
When examining the AGREE II ratings overall, the low-
est rating was in assessing the guideline description of
barriers and facilitators, implementation, resource impli-
cations, or monitoring/auditing criteria (Domain 5). In
fact, few guidelines had discrete sections addressing
knowledge translation. The concern about guideline ap-
plicability was explored in a 2015 systematic review [51],
which found that applicability scored lower than any
other domain [51, 52]. If guidelines rarely address their
implementation in practice, then there will be continued
practice variation. There is clear evidence supporting the
use of implementation tools to improve guideline uptake
[51]. Thus making guidelines without a clear knowledge
translation plan does a disservice to stakeholders [51].
The engagement of patients and caregivers was not-
ably absent in CPG development. This process is import-
ant, as it is aimed at improving implementability, by
ensuring the recommendations are comprehensive,
adaptable and applicable to the target group and have an
open process [53]. Given the constant changing nature
of evidence, having up-to-date guidelines certainly
makes a difference to the validity [32]. However, the low-
est rated item was for the guideline update procedures.
Guideline content
There is an overall lack of recommendations related to
the diagnosis or treatment of anxiety in either PD or de-
mentia. This stems from the fact there is little evidence
on how to approach the assessment. One guideline sug-
gested the use Hospital Anxiety and Depression Scale
for dementia, but they did not provide diagnostic accur-
acy information or suggestions for implementation [42].
There is also a concern that the medications traditionally
used for anxiety can have major adverse effects [35], and
there are few studies to guide treatment. Anxiety was
less frequently mentioned than depression in the in-
cluded CPGs, and in some cases was only mentioned in
combination with other neuropsychiatric symptoms. The
overall lack of evidence for anxiety care in PD and de-
mentia is a major gap in the current research.
Guidance for depression was present in a higher pro-
portion of guidelines. Despite this, there is variability in
the reporting of levels of evidence and recommenda-
tions (Additional file 3: Figure S1). In some cases the
recommendations for depression in PD only had 1 or 2
guidelines supporting them, indicating variance in
guideline reporting. In other cases recommendations
were vague, which can lead to difficulty with end user
interpretation and implementation [36].
It is clear that screening for depression with a vali-
dated tool in PD is recommended, although evidence
varies [37, 38]. It is recommended, as a good practice
point, that any diagnosis of depression is not made solely
on a brief assessment tool, as these tools are more focused
on case finding [37]. Although this is an important con-
cept in detection, it was only recommended by one guide-
line [54]. A 2015 systematic review identified several
validated tools for the detection of depression in PD, with
the GDS-15 having the highest pooled sensitivity (0.81;
95% CI 0.64, 0.91) and area under the curve (0.94) [55].
Recommendations surrounding non-pharmacologic
therapy were few, stating there was insufficient evidence
for the use of psychotherapy, ECT or TMS [34, 39, 40].
Two recent trials demonstrated the effectiveness of cog-
nitive behavioural therapy in PD [56, 57]. This highlights
the need for further large high quality studies on a range
of non-pharmacologic therapies and the need for con-
stant update of guidelines. Pharmacological therapy is
recommended for managing depression in PD, but there
is little evidence on choosing agents [39, 54]. This has
resulted in a variety of treatment recommendations, with
little evidence to direct clinical practice.
Depression in dementia was more frequently addressed.
However, these recommendations also had varied
guideline and evidentiary support. Guidelines supported
the evaluation of depression in dementia, but evidence
ranged from high quality to good practice points [41–45].
Commonly recommended tools were the CSDD and GDS,
with preference towards the CSDD due to better accur-
acy [39, 42, 45, 47, 48]. This was confirmed by a 2015
systematic review of depression tools for dementia,
finding that the CSDD had a area under the curve of
0.89 [58].
Interestingly, the issue of evaluating for suicide risk
was raised in two guidelines with divergent recommen-
dations [39, 46]. One stating there was inconclusive evi-
dence [46] and another stating substantial evidence [39].
It is unclear why there is such a difference in reported
evidence; perhaps development groups have different
evidence available or differing interpretations of the
evidence.
There are stronger recommendations for non-
pharmacologic treatment in dementia than in PD, outlin-
ing several options [41, 42, 45, 47, 48]. The evidence for
pharmacologic therapy is described as mixed with Grade
2A (Moderate Recommendation, High Level Evidence) to
Class IV (Un-blinded Study, Expert Opinion) [39, 41, 44,
45, 49, 50]. Again SSRIs and TCAs are the focus, with
TCAs being less likely to be recommended due to side
effects [39, 42, 45, 47, 50]. For those with dementia,
there were more options recommended for therapy in-
cluding stimulants, cholinesterase inhibitors and ECT
[39, 42].
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Limitations
There is a well-recognized issue with heterogeneity in
the terms used to refer to guidelines [52]. For our database
search we used indexed terms from each of the three data-
bases as well as key words using known nomenclature for
guidelines and the comorbidities. It is also possible that
the addition of the depression or anxiety criteria to the
search may have been restrictive, however without these
terms the search was impractical. To address this, we de-
veloped the search strategy with experts in the area of
guideline systematic review and an experienced librarian,
and we had an external reviewer independently assess the
search strategy. To reduce the risk of missing literature
not indexed in databases we contacted experts, searched
references of included studies and performed an extensive
search of the grey literature search.
Conclusions
Given the burden of comorbid mental illness in demen-
tia and PD, it is key that we understand clearly the
current knowledge base so we can improve care for
these populations. This study provides a synthesis and
quality assessment of the relevant guidelines. By synthe-
sizing the recommendations, we identified areas of
knowledge that are potentially ready to be translated
into practice but also clear evidence gaps. This data was
further evaluated in a subsequent study by stakeholders
in focus groups to understand the other barriers and fa-
cilitators to the use of guidelines. This was to inform
and help develop a comprehensive knowledge/end-user
focused plan for addressing these gaps.
Additional files
Additional file 1: Box S1. Search Strategy. (DOCX 22 kb)
Additional file 2: Table S1. Grey Literature Sources (n = 83). (DOCX 15 kb)
Additional file 3: Figure S1. Evidence Levels & Grading Schemes Used
Across Guidelines [34–49, 59]. (DOCX 65.4 kb)
Additional file 4: Table S2. Mean Domain Question Scores From
AGREE II Evaluation. (DOCX 16 kb)
Abbreviations
AAN: American Academy of Neurology; APA: American Psychiatric
Association; AIAQS: Agency for Health Quality and Assessment of Catalonia;
Avalia-T: Galician Health Technology Assessment Agency; BDI: Beck
Depression Inventory; BPA: British Association of Psychopharmacology;
CADASIL: Cerebral Autosomal-Dominant Arteriopathy with Subcortical
Infarcts and Leukoencephalopathy; CCCDTD4: Canadian Consensus
Conference on the Diagnosis and Treatment of Dementia; CNSF: Canadian
Neurological Sciences Foundation; CPG: Clinical Practice Guideline;
CRCD: Clinical Research Centre for Dementia; CSDD: Cornell Scale for
Depression in Dementia; DMAS: Dementia Mood Assessment Scale;
ECT: Electroconvulsive Therapy; EFNS: European Federation of Neuroscience;
GDS: Geriatric Depression Scale; GRADE: Grading of Recommendations
Assessment, Development and Evaluation; HADS: Hospital Anxiety and
Depression Scale; HDRS: Hamilton Depression Rating Scale; ICSI: Institute for
Clinical Systems Improvement; MADRS: Montgomery Åsberg Depression
Rating Scale; MDS: Movement Disorders Society; NICE: National Institute of
Clinical Excellence; PD: Parkinson’s Disease; PLM: Periodic Limb Movement
Syndrome; PRESS: Peer Review of Electronic Search Strategies;
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-
Analyses; RBD: REM Sleep Behaviour Disorder; RCT: Randomized Control Trial;
REM: Rapid Eye Movement; RLS: Restless Legs Syndrome; SD: Standard
Deviation; SIGN: Scottish Intercollegiate Guidelines Network; SSRI: Selective
Serotonin Reuptake Inhibitor; TCA: Tricyclic Acid Antidepressants;
TCMS: Transcranial Magnetic Stimulation; UPDRS: Unified Parkinson’s Disease
Rating Scale; WFBSP: World Federation of Societies of Behavioural Psychiatry;
WHO: World Health Organization
Acknowledgements
The authors would like to thank Diane Lorenzetti MLS, Research Librarian
(DL) for her input into the search strategy, and Helen Lee Robertson MLIS,
Liaison Librarian for Clinical Medicine for her (Peer Review of Electronic
Search Strategies) PRESS review of our search strategy.
Funding
This project had funding from an Alberta Innovates Health
Solutions—Knowledge to Action Grant.
Availability of data and material
The datasets during and/or analysed during the current study available from
the corresponding author on reasonable request. All data from this study are
presented in detail. For the quality assessment the individual ratings are not
published as the AGREE group recommends publication f the mean scaled
domain scores. The extracted recommendations are summarized in the
tables and text, full details are available in the source guidelines.
Authors’ contributions
ZG and BM performed all citation/full text screening, quality assessments,
data extraction and analysis and drafted the manuscript. ZG completed all
statistical analysis. SG was involved in the grey literature search and quality
assessment. JHL supervised all parts of the systematic review and analysis,
was involved in the quality assessment and determination of inclusion. ZG,
BM, SG, HH, SS, TP, NJ and JHL provided input and reviewed the proposal,
protocol, analysis and manuscript. ZG registered the protocol with
PROSPERO [58]. All authors had access to the data, reviewed and approved
the final manuscript. ZG and JHL had full access to the data in the study and
take responsibility for the integrity of the data and accuracy of the data.
Competing interests
ZG has received funding by Canadian Institutes for Health
Research—Canadian Graduate Student Scholarship, Alberta Innovates Health
Solutions Clinician Fellowship Award, Canadian Society for Clinical
Investigation Resident Research Award, Alberta Student and Western
Regional Training Centre affiliate award. BM and SG report no disclosures. HH
has no disclosures. SP holds funding from Hotchkiss Brain Institute (HBI),
CIHR and a grant co-funded by the University of Calgary HBI and Pfizer
Canada. TP has an unrestricted educational grants from Shire Canada. TP has
research grant support from Sick Kids Foundation, Alberta Health Services
Mental Health Strategic Clinical Network, Hotchkiss Brain Institute and
Canadian Institutes for Health Research. NJ holds a Canada Research Chair
Tier 2 in Health Services Research and is on the editorial board of Neurology
and holds research grants from the Canadian Institutes of Health Research,
Alberta Innovates Health Solutions, the Alberta Spine Foundation, the
University of Calgary Cumming School of Medicine, Department of Clinical
Neurosciences and HBIs and a grant co-funded by the University of Calgary
HBI and Pfizer Canada. JHL has received funding from Alberta Health Services
as the Scientific Director of the Seniors Health Strategic Clinical Network.
Consent for publication
Not Applicable.
Ethics approval and consent to participate
University of Calgary Conjoint Health Research Ethics Board (CHREB) REB
14-1449
Author details
1Department of Community Health Sciences, University of Calgary, Calgary,
Canada. 2Department of Medicine, University of Calgary and Alberta Health
Goodarzi et al. BMC Neurology  (2016) 16:244 Page 11 of 13
Services, Calgary, Canada. 3Faculty of Medicine, Undergraduate Medical
Education, University of Toronto, Toronto, Canada. 4Seniors Health Strategic
Clinical Network, Alberta Health Services, Alberta, Canada. 5Department of
Clinical Neurosciences, University of Calgary, Calgary, Canada. 6Hotchkiss
Brain Institute, and O’Brien Institute for Public Health, University of Calgary
and Alberta Health Services, Calgary, Canada. 7Department of Psychiatry and
Pediatrics, University of Calgary and Alberta Health Services, Calgary, Canada.
8Department of Psychiatry, University of Calgary and Alberta Health Services,
Calgary, Canada. 9Mathison Centre for Mental Health Research and
Education, University of Calgary, Calgary, Canada. 10#1104-South Tower.
Foothills Medical Centre 3301 Hospital Drive, Calgary, NW T2N 2T9, Canada.
Received: 30 June 2016 Accepted: 10 November 2016
References
1. Pachana NA, Egan SJ, Laidlaw K, Dissanayaka N, Byrne GJ, Brockman S,
Marsh R, Starkstein S. Clinical issues in the treatment of anxiety and
depression in older adults with Parkinson’s disease. Movement disorders:
official journal of the Movement Disorder Society. 2013;28(14):1930–4.
2. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic
review of prevalence studies of depression in Parkinson’s disease. Mov
Disord. 2008;23(2):183–9. quiz 313.
3. Schrag A, Leentjens AF. Parkinson disease: scales to detect depression in
Parkinson disease. Nat Rev Neurol. 2012;8(7):359–60.
4. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric
and other nonmotor symptoms on disability in Parkinson’s disease. J Am
Geriatr Soc. 2004;52(5):784–8.
5. Kostic VS, Pekmezovic T, Tomic A, Jecmenica-Lukic M, Stojkovic T, Spica V,
Svetel M, Stefanova E, Petrovic I, Dzoljic E. Suicide and suicidal ideation in
Parkinson’s disease. J Neurol Sci. 2010;289(1-2):40–3.
6. Hughes TA, Ross HF, Mindham RH, Spokes EG. Mortality in Parkinson’s
disease and its association with dementia and depression. Acta Neurol
Scand. 2004;110(2):118–23.
7. Orgeta V, Qazi A, Spector AE, Orrell M. Psychological treatments for
depression and anxiety in dementia and mild cognitive impairment.
Cochrane Database Syst Rev. 2014;1:CD009125.
8. Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, Bentham P,
Fox C, Holmes C, Katona C, et al. Sertraline or mirtazapine for depression in
dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-
controlled trial. Lancet. 2011;378(9789):403–11.
9. Enache D, Winblad B, Aarsland D. Depression in dementia: epidemiology,
mechanisms, and treatment. Curr Opin Psychiatry. 2011;24(6):461–72.
10. Riley RJ, Burgener S, Buckwalter KC. Anxiety and stigma in dementia: a
threat to aging in place. Nurs Clin North Am. 2014;49(2):213–31.
11. Van der Mussele S, Bekelaar K, Le Bastard N, Vermeiren Y, Saerens J, Somers
N, Marien P, Goeman J, De Deyn PP, Engelborghs S. Prevalence and
associated behavioral symptoms of depression in mild cognitive
impairment and dementia due to Alzheimer’s disease. Int J Geriatr
Psychiatry. 2013;28(9):947–58.
12. Dissanayaka NN, Sellbach A, Matheson S, O’Sullivan JD, Silburn PA, Byrne GJ,
Marsh R, Mellick GD. Anxiety disorders in Parkinson’s disease: prevalence
and risk factors. Mov Disord. 2010;25(7):838–45.
13. Marsh L. Depression and Parkinson’s disease: current knowledge. Curr
Neurol Neurosci Rep. 2013;13(12):409.
14. Djamshidian A, Friedman JH. Anxiety and depression in Parkinson’s disease.
Curr Treat Options Neurol. 2014;16(4):285.
15. Knapskog AB, Barca ML, Engedal K. A comparison of the validity of the
Cornell Scale and the MADRS in detecting depression among memory
clinic patients. Dement Geriatr Cogn Disord. 2011;32(4):287–94.
16. Modrego PJ, Ferrandez J. Depression in patients with mild cognitive
impairment increases the risk of developing dementia of Alzheimer type: a
prospective cohort study. Arch Neurol. 2004;61(8):1290–3.
17. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and
risk for Alzheimer disease: systematic review, meta-analysis, and
metaregression analysis. Arch Gen Psychiatry. 2006;63(5):530–8.
18. Frisina PG, Borod JC, Foldi NS, Tenenbaum HR. Depression in Parkinson’s
disease: health risks, etiology, and treatment options. Neuropsychiatr Dis
Treat. 2008;4(1):81–91.
19. Davis D, J. Goldman, P. Valerie: Handbook on Clinical Practice Guidelines. In.:
Canadian Medical Association; 2007.
20. Gagliardi AR, Brouwers MC, Palda VA, Lemieux-Charles L, Grimshaw JM. How
can we improve guideline use? A conceptual framework of implementability.
Implementation Sci. 2011;6:26. https://www.ncbi.nlm.nih.gov/pubmed/
21426574
21. Graham R, Mancher M, Miller-Wolman D, Greenfield S, Steinberg EH. Clinical
Practice Guidelines We Can Trust. Washington: Institute of Medicine (US)
Committee on Standards for Developing Trustworthy Clinical Practice
Guidelines. National Academy of Sciences; 2011.
22. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, Whitty
P, Eccles MP, Matowe L, Shirran L, et al. Effectiveness and efficiency of
guideline dissemination and implementation strategies. Health Technol
Assess. 2004;8(6):iii–iv. 1-72.
23. Ramasubbu R, Taylor VH, Samaan Z, Sockalingham S, Li M, Patten S, Rodin
G, Schaffer A, Beaulieu S, McIntyre RS, et al. The Canadian Network for
Mood and Anxiety Treatments (CANMAT) task force recommendations for
the management of patients with mood disorders and select comorbid
medical conditions. Ann Clin Psychiatry. 2012;24(1):91–109.
24. Ramasubbu R, Beaulieu S, Taylor VH, Schaffer A, McIntyre RS, Canadian
Network for M, Anxiety Treatments Task F. The CANMAT task force
recommendations for the management of patients with mood disorders
and comorbid medical conditions: diagnostic, assessment, and treatment
principles. Ann Clin Psychiatry. 2012;24(1):82–90.
25. Kerr MP, Mensah S, Besag F, de Toffol B, Ettinger A, Kanemoto K, Kanner A,
Kemp S, Krishnamoorthy E, LaFrance Jr WC, et al. International consensus
clinical practice statements for the treatment of neuropsychiatric conditions
associated with epilepsy. Epilepsia. 2011;52(11):2133–8.
26. Wilcock J, Iliffe S, Turner S, Bryans M, O’Carroll R, Keady J, Levin E, Downs M.
Concordance with clinical practice guidelines for dementia in general
practice. Aging Ment Health. 2009;13(2):155–61.
27. Salter K, McClure JA, Mahon H, Foley N, Teasell R. Adherence to Canadian
best practice recommendations for stroke care: assessment and
management of poststroke depression in an Ontario rehabilitation facility.
Top Stroke Rehabil. 2012;19(2):132–40.
28. McCluskey A, Vratsistas-Curto A, Schurr K. Barriers and enablers to
implementing multiple stroke guideline recommendations: a qualitative
study. BMC Health Serv Res. 2013;13:323.
29. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting
items for systematic reviews and meta-analyses: the PRISMA statement.
Bmj 2009, 339:b2535.
30. Making the Case for Investing in Mental Health in Canada. In.: Mental
Health Commission of Canada; 2013.
31. PRESS: peer review of electronic search strategies. 2015 Guideline
Explanation and Elaboration (PRESS E&E). Ottawa: Canadian Agency for
Drugs and Technologies in Health; 2016. https://www.cadth.ca/sites/default/
files/pdf/CP0015_PRESS_Update_Report_2016.pdf
32. Martinez Garcia L, Sanabria AJ, Garcia Alvarez E, Trujillo-Martin MM,
Etxeandia-Ikobaltzeta I, Kotzeva A, Rigau D, Louro-Gonzalez A, Barajas-Nava
L, Diaz Del Campo P, et al. The validity of recommendations from clinical
guidelines: a survival analysis. CMAJ. 2014;186(16):1211–9.
33. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers
B, Graham ID, Grimshaw J, Hanna SE, et al. AGREE II: advancing guideline
development, reporting and evaluation in health care. CMAJ. 2010;182(18):
E839–842.
34. Grimes D, Gordon J, Snelgrove B, Lim-Carter I, Fon E, Martin W, Wieler M,
Suchowersky O, Rajput A, Lafontaine AL, et al. Canadian guidelines on
Parkinson’s disease. Can J Neurol Sci. 2012;39(4 Suppl 4):S1–30.
35. Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth
GS, Miyasaki J, Iverson DJ, Weiner WJ, Quality Standards Subcommittee
of the American Academy of N. Practice parameter: treatment of
nonmotor symptoms of Parkinson disease: report of the quality standards
subcommittee of the American Academy of Neurology. Neurology. 2010;
74(11):924–31.
36. Michie S, Johnston M: Changing clinical behaviour by making guidelines
specific. Bmj 2004, 328(7435):343–345.
37. Diagnosis and pharmacological management of Parkinson’s disease: A
national clinical guideline. Scottish Intercollegiate Guidelines Network; 2010.
38. Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks
D, Burn DJ, Colosimo C, Fanciulli A, et al. EFNS/MDS-ES/ENS [corrected]
recommendations for the diagnosis of Parkinson’s disease. European journal
of neurology: the official journal of the European Federation of Neurological
Societies. 2013;20(1):16–34.
Goodarzi et al. BMC Neurology  (2016) 16:244 Page 12 of 13
39. Gelenberg AJ, Freeman MP, Markowitz JC, Rosenbaum JF, Thase ME, Trivedi
MH, Van Rhoads RS. Practice Guideline for Treatment of Patients with Major
Depressive Disorder 3rd Edition. American Pyschiatric Association; 2010.
40. Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G,
Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, et al. Summary of the
recommendations of the EFNS/MDS-ES review on therapeutic management
of Parkinson’s disease. Eur J Neurol. 2013;20(1):5–15. https://www.ncbi.nlm.
nih.gov/pubmed/23279439
41. Dementia: Guidelines on Supporting People with Dementia and their carers
in Health and Social Care. National Institute for Health and Clinical
Excellence. National Collaborating Centre for Mental Health. Social Care
Institute for Excellence National Institute for Health and Clinical Excellence.
In. London: The British Psychological Society & Gaskell The Royal College of
Psychiatrists; 2011.
42. Development Group of the Clinical Practice Guideline on the
comprehensive care of people with Alzheimer’s disease and other
dementias. Clinical Practice Guideline on the comprehensive care of people
with Alzheimer’s disease and other dementias. Quality Plan for the National
Health System of the Ministry of Health, Social Policies and Equality Agència
d’Informació, Avaluació i Qualitat en Salut of Catalonia Clinical Practice
Guidelines in the Spanish National Health Service: AIAQS No 2009/07 2010.
http://www.guiasalud.es/GPC/GPC_484_Alzheimer_AIAQS_comp_eng.pdf
43. Clinical Research Center for Dementia of South Korea. Clinical practice
guideline for dementia. Part I: diagnosis & evaluation. Seoul: Clinical
Research Center for Dementia of South Korea; 2011. p. 117. The guideline
cited is available here: http://jkma.org/src/SM/jkma-54-861-s002.pdf
44. Ihl R, Frolich L, Winblad B, Schneider L, Burns A, Moller HJ, Disease
WTFoTGfAs, other D. World Federation of Societies of Biological Psychiatry
(WFSBP) guidelines for the biological treatment of Alzheimer’s disease and
other dementias. World J Biol Psychiatry. 2011;12(1):2–32. https://www.ncbi.
nlm.nih.gov/pubmed/21288069
45. Sorbi S, Hort J, Erkinjuntti T, Fladby T, Gainotti G, Gurvit H, Nacmias B,
Pasquier F, Popescu BO, Rektorova I, et al. EFNS-ENS Guidelines on the
diagnosis and management of disorders associated with dementia. Eur J
Neurol. 2012;19(9):1159–79. https://www.ncbi.nlm.nih.gov/pubmed/
22891773
46. Working Group of the Clinical Practice Guideline for the Prevention and
Treatment [trunc]. Clinical practice guideline for the prevention and
treatment of suicidal behaviour. Madrid: Ministry of Health and Social Policy,
Galician Health Technology Assessment Agency; 2012. p. 382. http://www.
guiasalud.es/GPC/GPC_481_Conducta_Suicida_Avaliat_compl_en.pdf
47. Hort J, O’Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S,
Scheltens P, Dementia ESPo. EFNS guidelines for the diagnosis and
management of Alzheimer’s disease. Eur J Neurol. 2010;17(10):1236–48.
48. Mitchell J, Trangle M, Degnan B, Gabert T, Haight B, Kessler D, Mack N,
Mallen E, Novak H, Rossmiller D, et al. Adult Depression in Primary Care.
Institute for Clinical Systems Improvement; 2013.
49. Dua T, Barbui C, Clark N, Fleischmann A, Poznyak V, van Ommeren M,
Yasamy MT, Ayuso-Mateos JL, Birbeck GL, Drummond C, et al. Evidence-
based guidelines for mental, neurological, and substance use disorders in
low- and middle-income countries: summary of WHO recommendations.
PLoS Med. 2011;8(11):e1001122. https://www.ncbi.nlm.nih.gov/pubmed/
22110406
50. Gauthier S, Patterson C, Chertkow H, Gordon M, Herrmann N, Rockwood K,
Rosa-Neto P, Soucy JP. Recommendations of the 4th Canadian consensus
conference on the diagnosis and treatment of dementia (CCCDTD4). Can
Geriatr J. 2012;15(4):120–6.
51. Gagliardi AR, Brouwers MC. Do guidelines offer implementation advice to
target users? A systematic review of guideline applicability. BMJ Open. 2015;
5(2):e007047.
52. Sauro KM, Wiebe S, Dunkley C, Janszky J, Kumlien E, Moshe S, Nakasato N,
Pedley TA, Perucca E, Senties H, et al. The current state of epilepsy
guidelines: A systematic review. Epilepsia. 2016;57(1):13–23.
53. Eccles MP, Grimshaw JM, Shekelle P, Schunemann HJ, Woolf S. Developing
clinical practice guidelines: target audiences, identifying topics for
guidelines, guideline group composition and functioning and conflicts of
interest. Implementation Sci. 2012;7:60.
54. Grosset DG, Macphee GJ, Nairn M, Guideline Development G. Diagnosis and
pharmacological management of Parkinson’s disease: summary of SIGN
guidelines. BMJ. 2010;340:b5614.
55. Goodarzi ZS, Mrklas K, Roberts DJ, Jette N, Pringsheim T, Holroyd-Leduc J.
Depression case finding in Parkinson’s disease patients: a systematic review
of depression screening tools. Montreal: Canadian Geriatric Society Scientific
Meeting 2015; 2015.
56. Dobkin RD, Menza M, Allen LA, Gara MA, Mark MH, Tiu J, Bienfait KL, Friedman
J. Cognitive-behavioral therapy for depression in Parkinson’s disease: a
randomized, controlled trial. Am J Psychiatry. 2011;168(10):1066–74.
57. Troeung L, Egan SJ, Gasson N. A waitlist-controlled trial of group cognitive
behavioural therapy for depression and anxiety in Parkinson’s disease. BMC
Psychiatry. 2014;14:19.
58. Goodarzi Z, Mele B, Roberts D, Holroyd-Leduc J. Depression case finding in
dementia patients: a systematic review of depression screening tools.
Ottawa: Canadian Conference on Dementia Meeting 2015; 2015.
59. Guidance notes for registering a systematic review protocol with
PROSPERO. In: PROSPERO: International prospective register of systematic
reviews Centre for Reviews and Dissemination, National Institute for Health
Research; 2013.
60. O’Brien JT, Burns A, Group BAPDC. Clinical practice with anti-dementia
drugs: a revised (second) consensus statement from the British Association
for Psychopharmacology. J Psychopharmacol. 2011;25(8):997–1019. https://
www.ncbi.nlm.nih.gov/pubmed/21088041
61. Patel T, Chang F, Parkinson Society C. Parkinson’s disease guidelines for
pharmacists. Can Pharm J. 2014;147(3):161–70.
62. Moore A, Patterson C, Lee L, Vedel I, Bergman H, Canadian Consensus
Conference on the D, Treatment of D. Fourth Canadian Consensus Conference
on the Diagnosis and Treatment of Dementia: recommendations for family
physicians. Can Fam Physician. 2014;60(5):433–8.
63. Herrmann N, Lanctot KL, Hogan DB. Pharmacological recommendations for
the symptomatic treatment of dementia: the Canadian Consensus
Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimer’s
Res Ther. 2013;5 Suppl 1:S5. https://www.ncbi.nlm.nih.gov/pubmed/
24565367
64. Rabins PV, Blacker D, Rovner BW, Rummans T, Schneider LS, Tariot PN, Blass
DM. Practice Guidelines for the Treatment of Patients With Alzheimer’s
Disease and Other Dementias. American Pyschiatric Association; 2007.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Goodarzi et al. BMC Neurology  (2016) 16:244 Page 13 of 13
